Research / Laboratory

Successful Clinical to Commercial Bioconjugate Manufacturing

Partnering with a Trusted CDMO Helps to Manage the Complexity of Increased Molecule Diversification

Ever since antibody drug conjugates (ADCs) were first reported in the 1970s, the field of bioconjugation has found itself in a constant state of evolution.

Modalities now extend beyond traditional ADCs; novel conjugate formats such as antibody chelator, antibody oligonucleotide, antibody polymer, and modified protein conjugates are currently in development. Target binding formats and conjugation technologies have also become increasingly diverse.  

By partnering with an experienced CDMO, you will get the help you need to manage the complexity that comes with increased molecule diversification. At Lonza, our dedicated manufacturing, science and technology (MSAT) team are there to guide you through each step of the development and manufacturing process, be it optimization, scale-up, or validation. We always shape our collaboration to meet your needs, no matter which stage you are at in your development process. Our MSAT team can help you transition smoothly and efficiently from process development to clinical or commercial manufacturing.  

Read our white paper and learn how we can help you achieve high-quantity, quality product and accelerate your timelines to commercial manufacturing.


Sponsored by



Lonza AG

Muenchensteinerstrasse 38
4002 Basel